Nautilus Biotechnolgy, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sujal Patel
- Full Time Employees
- 127
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2701 Eastlake Avenue East Seattle WA United States of America 98102
- IPO Date
- Aug 7, 2020
- CIK
- 0001808805
- Website
- nautilus.bio
- Similar Companies
- Business
- Nautilus Biotechnology, Inc. is a life sciences firm focused on developing a groundbreaking platform for comprehensive proteome analysis. This innovative company is actively creating the Nautilus Platform, a complete solution designed for single-molecule protein detection, encompassing sophisticated instruments, specialized consumables, and advanced software for data interpretation. Established in 2016 and based in Seattle, Washington, the enterprise is set to revolutionize biological discovery and drug development by providing unprecedented depth and precision in understanding protein function. The company's unique technology aims to reveal low-abundance proteins and their precise modifications, advancing beyond the capabilities of conventional methods. Recently, Nautilus reported the successful deployment and evaluation of its initial field unit at the Buck Institute for Research on Aging and continues to prepare for its anticipated commercial launch in 2026.
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
3 Small-Cap Stocks to Buy Before May 15
Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
26,324 Shares in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Purchased by Squarepoint Ops LLC
Nautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call Transcript
Nautilus: Trading Below An Albeit Lower Net Cash Figure
Nautilus Biotechnology, Inc. (NAUT) Q4 2024 Earnings Call Transcript
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award